Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy
Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
J Neurol Neurosurg Psychiatry. 2020 Apr;91(4):426-433. doi: 10.1136/jnnp-2019-322169. Epub 2020 Feb 20.
Genetic subtypes of dystonia may respond differentially to deep brain stimulation of the globus pallidus pars interna (GPi DBS). We sought to compare GPi DBS outcomes among the most common monogenic dystonias.
This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses and Meta-analysis of Observational Studies in Epidemiology guidelines. We searched PubMed for studies on genetically confirmed monogenic dystonia treated with GPi DBS documenting pre-surgical and post-surgical assessments using the Burke-Fahn-Marsden Dystonia Rating Scale Motor Score (BFMMS) and Burke-Fahn-Marsden Disability Score (BFMDS). We performed (i) meta-analysis for each gene mutation; (ii) weighted ordinary linear regression analyses to compare BFMMS and BFMDS outcomes between DYT- and other monogenic dystonias, adjusting for age and disease duration and (iii) weighted linear regression analysis to estimate the effect of age, sex and disease duration on GPi DBS outcomes. Results were summarised with mean change and 95% CI.
DYT- (68%, 38.4 points; p<0.001), DYT- (37% 14.5 points; p<0.001) and NBIA/DYT- (27%, 21.4 points; p<0.001) improved in BFMMS; only DYT- improved in BFMDS (69%, 9.7 points; p<0.001). Improvement in DYT- was significantly greater than in DYT- (BFMMS -31%), NBIA/DYT- (BFMMS -35%; BFMDS -53%) and CHOR/DYT- (BFMMS -36%; BFMDS -42%). Worse motor outcomes were associated with longer dystonia duration and older age at dystonia onset in DYT-, longer dystonia duration in DYT/PARK- and younger age at dystonia onset in DYT-.
GPi DBS outcomes vary across monogenic dystonias. These data serve to inform patient selection and prognostic counselling.
遗传型肌张力障碍的亚型可能对苍白球内侧部(GPi)的深部脑刺激(DBS)有不同的反应。我们旨在比较最常见的单基因性肌张力障碍的 GPi-DBS 结果。
本系统评价和荟萃分析遵循系统评价和荟萃分析的首选报告项目以及观察性研究的荟萃分析流行病学指南。我们在 PubMed 上搜索了使用 Burke-Fahn-Marsden 肌张力障碍评定量表运动评分(BFMMS)和 Burke-Fahn-Marsden 残疾评分(BFMDS)记录术前和术后评估的经基因证实的单基因性肌张力障碍接受 GPi-DBS 治疗的研究。我们进行了(i)每个基因突变的荟萃分析;(ii)加权普通线性回归分析,以比较 DYT-和其他单基因性肌张力障碍的 BFMMS 和 BFMDS 结果,调整年龄和疾病持续时间;(iii)加权线性回归分析,以估计年龄、性别和疾病持续时间对 GPi-DBS 结果的影响。结果以平均变化和 95%置信区间表示。
DYT-(68%,38.4 分;p<0.001)、DYT-(37%,14.5 分;p<0.001)和 NBIA/DYT-(27%,21.4 分;p<0.001)的 BFMMS 均有改善;只有 DYT-的 BFMDS 有所改善(69%,9.7 分;p<0.001)。DYT-的改善明显大于 DYT-(BFMMS-31%)、NBIA/DYT-(BFMMS-35%;BFMDS-53%)和 CHOR/DYT-(BFMMS-36%;BFMDS-42%)。在 DYT-中,较差的运动结果与较长的肌张力障碍持续时间和发病年龄较大有关;在 DYT/PARK-中,与较长的肌张力障碍持续时间有关;在 DYT-中,与发病年龄较小有关。
GPi-DBS 的结果在不同的单基因性肌张力障碍中有所不同。这些数据有助于为患者选择和预后咨询提供信息。